PolyPeptide Group AG Logo

PolyPeptide Group AG

PPGN | SW

Overview

Corporate Details

ISIN(s):
CH1110760852
LEI:
5067007JCKTPOX4G9758
Country:
Switzerland
Address:
Neuhofstrasse 24, 6340 Baar
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PolyPeptide Group AG is a global Contract Development & Manufacturing Organization (CDMO) specializing in peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). The company provides comprehensive services to pharmaceutical and biotech partners, supporting the development and manufacturing of both proprietary and generic products. PolyPeptide assists clients throughout the product lifecycle, from initial development to regulatory approval and commercial launch. A key focus is on innovation in large-scale production and sustainable manufacturing processes, such as green peptide chemistry, to enhance process performance while minimizing environmental impact.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for PolyPeptide Group AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-12 06:55
Earnings Release
PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian …
English 31.7 KB
2025-08-12 02:00
Earnings Release
PolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian …
English 28.4 KB
2025-08-12 02:00
Earnings Release
PolyPeptide wächst im ersten Halbjahr 2025 um 24%, mit einer erfolgreichen Anla…
German 32.6 KB
2025-05-23 07:00
Capital/Financing Update
PolyPeptide announces expansion of existing credit facilities
English 7.8 KB
2025-05-23 02:00
Capital/Financing Update
PolyPeptide announces expansion of existing credit facilities
English 6.0 KB
2025-05-23 02:00
Capital/Financing Update
PolyPeptide gibt Ausweitung des bestehenden Kreditrahmens bekannt
German 7.0 KB
2025-04-09 18:34
Post-Annual General Meeting Information
PolyPeptide announces results of the annual General Meeting 2025
English 9.3 KB
2025-03-19 07:00
Pre-Annual General Meeting Information
PolyPeptide publishes invitation to the annual General Meeting 2025
English 8.8 KB
2025-03-18 07:00
Pre-Annual General Meeting Information
PolyPeptide publishes invitation to the annual General Meeting 2025
English 8.8 KB
2025-03-18 01:00
Pre-Annual General Meeting Information
PolyPeptide publishes invitation to the annual General Meeting 2025
English 7.1 KB
2025-03-18 01:00
Pre-Annual General Meeting Information
PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2025
German 8.0 KB
2025-03-12 06:55
Earnings Release
PolyPeptide with substantial improvements in profitability and cash flow, posit…
English 32.1 KB
2025-03-11 06:55
Earnings Release
PolyPeptide with substantial improvements in profitability and cash flow, posit…
English 32.1 KB
2025-03-11 01:00
Earnings Release
PolyPeptide with substantial improvements in profitability and cash flow, posit…
English 28.2 KB
2025-03-11 01:00
Earnings Release
PolyPeptide mit substantiellen Verbesserungen bei Profitabilität und Cashflow, …
German 32.0 KB

Automate Your Workflow. Get a real-time feed of all PolyPeptide Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PolyPeptide Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-09 N/A Non-Executive member Buy None 75,000.00 CHF
2025-04-09 N/A Non-Executive member Buy None 72,000.00 CHF
2025-04-09 N/A Non-Executive member Buy None 50,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 75,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 72,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 50,000.00 CHF
2024-04-11 N/A Non-Executive member Buy None 35,000.00 CHF
2023-11-10 N/A Executive member Buy None 51,250.00 CHF
2023-10-11 N/A Executive member Buy None 2,876,348.62 CHF
2023-10-10 N/A Executive member Buy None 371,202.96 CHF

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK